Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Khaoula Errafii"'
Autor:
Yasser Al-Sarraj, Rowaida Z. Taha, Eman Al-Dous, Dina Ahram, Somayyeh Abbasi, Eman Abuazab, Hibah Shaath, Wesal Habbab, Khaoula Errafii, Yosra Bejaoui, Maryam AlMotawa, Namat Khattab, Yasmin Abu Aqel, Karim E. Shalaby, Amina Al-Ansari, Marios Kambouris, Adel Abouzohri, Iman Ghazal, Mohammed Tolfat, Fouad Alshaban, Hatem El-Shanti, Omar M. E. Albagha
Publikováno v:
Frontiers in Genetics, Vol 15 (2024)
Introduction: Autism spectrum disorder (ASD) is characterized by aberrations in social interaction and communication associated with repetitive behaviors and interests, with strong clinical heterogeneity. Genetic factors play an important role in ASD
Externí odkaz:
https://doaj.org/article/1cb66fb1f0d64cfb9ab254e423381745
Autor:
Khaoula Errafii, Amin Jayyous, Abdelillah Arredouani, Hasan Khatib, Fouad Azizi, Ramzi M. Mohammad, Muhammad Abdul-Ghani, Mohamed Chikri
Publikováno v:
All Life, Vol 15, Iss 1, Pp 191-202 (2022)
Insulin resistance (IR) is type 2 diabetes’ hallmark. MiRNAs regulate many target genes that makes them attractive candidates for regulating insulin production, secretion and action. Therefore, we anticipate a change in the circulatory profile of m
Externí odkaz:
https://doaj.org/article/7635388a4c8349638826ee9d7fb25f34
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Non-alcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Agonists of the glucagon-like peptide-1 receptor (GLP-1R), currently approved to treat type 2 diabetes, hold promise to improve steatosis and even stea
Externí odkaz:
https://doaj.org/article/ef51255aefbf4f36b4ac60b9ceb73882
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Elevated serum ferritin (SFer) levels are implicated in many energy metabolism abnormalities. The association between SFer levels and metabolic disorders has not been studied in Middle Eastern populations. We aimed at exploring the associati
Externí odkaz:
https://doaj.org/article/84c8070d95334a1f8470f6c106eb0bf4
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11606 (2023)
Excess hepatic lipid accumulation is the hallmark of non-alcoholic fatty liver disease (NAFLD), for which no medication is currently approved. However, glucagon-like peptide-1 receptor agonists (GLP-1RAs), already approved for treating type 2 diabete
Externí odkaz:
https://doaj.org/article/dc69079b3b6440eca7f602a2fe2dda7d
Autor:
Mostafa Abbas, Raghvendra Mall, Khaoula Errafii, Abdelkader Lattab, Ehsan Ullah, Halima Bensmail, Abdelilah Arredouani
Publikováno v:
Journal of Diabetes Investigation, Vol 12, Iss 6, Pp 988-997 (2021)
Abstract Aims/Introduction The progression from prediabetes to type 2 diabetes is preventable by lifestyle intervention and/or pharmacotherapy in a large fraction of individuals with prediabetes. Our objective was to develop a risk score to screen fo
Externí odkaz:
https://doaj.org/article/8b37c52836f743ec9e494e9f83a4b244
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-11 (2021)
Abstract Background and aims The hallmark of non-alcoholic fatty liver disease (NAFLD) is the excessive hepatic lipid accumulation. Currently, no pharmacotherapy exists for NAFLD. However, the glucagon-like peptide-1 receptor agonists have recently e
Externí odkaz:
https://doaj.org/article/27d947c8f2114284985e57f923e3d031
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 7, p 6337 (2023)
Understanding the role of white adipose tissue (WAT) in the occurrence and progression of metabolic syndrome is of considerable interest; among the metabolic syndromes are obesity and type 2 diabetes (T2D). Insulin resistance is a key factor in the d
Externí odkaz:
https://doaj.org/article/4574bd8e4b5b4f378d0b0aef1d2abaaa
Autor:
Nuha T. Swaidan, Salam Salloum-Asfar, Freshteh Palangi, Khaoula Errafii, Nada H. Soliman, Ahmed T. Aboughalia, Abdul Haseeb S. Wali, Sara A. Abdulla, Mohamed M. Emara
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-19 (2020)
Abstract Although many factors have been identified and used to enhance the iPSC reprogramming process, its efficiency remains quite low. In addition, reprogramming efficacy has been evidenced to be affected by disease mutations that are present in p
Externí odkaz:
https://doaj.org/article/7ae603a437084f20abc470cc1eac7cb6
Publikováno v:
Biomedicines, Vol 10, Iss 5, p 1020 (2022)
No therapy exists for non-alcoholic fatty liver disease (NAFLD). However, glucagon-like peptide receptor agonists (GLP-1RAs) showed a beneficial effect on NAFLD, although the underpinning mechanisms remain unclear due to their pleiotropic effects. We
Externí odkaz:
https://doaj.org/article/a61e0cdcc52b43289d621b25c1cfe39e